Dr. Roussos Torres on the Importance of Preclinical Models in HER2+ Breast Cancer

Evanthia Roussos Torres, MD
Published: Friday, Jun 08, 2018



Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

A missing but necessary component of immunotherapy research in HER2-positive breast cancer is the use of preclinical data, says Roussos Torres. This could answer the question as to why there are responders and non-responders to this type of therapy. Preclinical work can help guide decisions regarding combinations and clinical trial development, Roussos adds. This could propel this area of breast cancer research forwards, she explains.

For example, the epigenetic modulator entinostat has shown signals of improvement in the immunosuppressive tumor microenvironment of mice with HER2-positive tumors, making it more amenable to checkpoint inhibition. This approach may improve response rates in HER2-positive breast cancer.
SELECTED
LANGUAGE


Evanthia Roussos Torres, MD, oncology fellow, Johns Hopkins University School of Medicine, discusses the importance of preclinical models in HER2-positive breast cancer.

A missing but necessary component of immunotherapy research in HER2-positive breast cancer is the use of preclinical data, says Roussos Torres. This could answer the question as to why there are responders and non-responders to this type of therapy. Preclinical work can help guide decisions regarding combinations and clinical trial development, Roussos adds. This could propel this area of breast cancer research forwards, she explains.

For example, the epigenetic modulator entinostat has shown signals of improvement in the immunosuppressive tumor microenvironment of mice with HER2-positive tumors, making it more amenable to checkpoint inhibition. This approach may improve response rates in HER2-positive breast cancer.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x